Patient survey on cancer genomic medicine in Japan under the national health insurance system
Cancer Science · 2024-03 · 115 (3) · 954-962
DOI: 10.1111/cas.16065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 26.01.2024. Verfasst von Hidenori Kage und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Genomic Medicine, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
In Japan, comprehensive genomic profiling (CGP) tests have been reimbursed under the national health care system for solid cancer patients who have finished standard treatment. More than 50,000 patients have taken the test since June 2019. We performed a nation‐wide questionnaire survey between March 2021 and July 2022. Questionnaires were sent to 80 designated Cancer Genomic Medicine Hospitals. Of the 933 responses received, 370 (39.7%) were web based and 563 (60.3%) were paper based. Most patients (784, 84%) first learned about CGP tests from healthcare professionals, and 775 (83.1%) gave informed consent to their treating physician. At the time of informed consent, they were most worried about test results not leading to novel treatment (536, 57.4%). On a scale of 0–10, 702 respondents (75.2%) felt that the explanations of the test result were easy to understand (7 or higher). Ninety‐one patients (9.8%) started their recommended treatment. Many patients could not receive recommended treatment because no approved drugs or clinical trials were available (102/177, 57.6%). Ninety‐eight patients (10.5%) did not wish their findings to be disclosed. Overall satisfaction with the CGP test process was high, with 602 respondents (64.5%) giving a score of 7–10. The major reason for choosing 0–6 was that the CGP test result did not lead to new treatment (217/277, 78.3%). In conclusion, satisfaction with the CGP test process was high. Patients and family members need better access to information. More patients need to be treated with genomically matched therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.
- Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Public Policy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ORCID-Profile: Hidenori Kage, Manabu Muto, Katsuya Tsuchihara, Hidekazu Shirota, Hideyuki Hayashi, Toshio Kokuryo, Shinichi Yachida, Akira Hirasawa, Hirotsugu Kenmotsu, Masahiko Tanabe, Katsutoshi Oda
Förderung
- Ministry of Health, Labour and Welfare
Zitieren
APA
Kage, H., Akiyama, N., Chang, H., Shinozaki-Ushiku, A., Ka, M., Kawata, J., Muto, M., Okuma, Y., Okita, N., Tsuchihara, K., Kikuchi, J., Shirota, H., Hayashi, H., Kokuryo, T., Yachida, S., Hirasawa, A., Kubo, M., Kenmotsu, H., Tanabe, M., …, & Oda, K. (2024). Patient survey on cancer genomic medicine in Japan under the national health insurance system. Cancer Science, 115(3), 954-962. https://doi.org/10.1111/cas.16065
Vancouver
Kage H, Akiyama N, Chang H, Shinozaki-Ushiku A, Ka M, Kawata J, et al. Patient survey on cancer genomic medicine in Japan under the national health insurance system. Cancer Science. 2024;115(3):954-962. doi:10.1111/cas.16065
BibTeX
@article{Kage2024,
author = {Kage, Hidenori and Akiyama, Nana and Chang, Hyangri and Shinozaki-Ushiku, Aya and Ka, Mirei and Kawata, Junichi and Muto, Manabu and Okuma, Yusuke and Okita, Natsuko and Tsuchihara, Katsuya and Kikuchi, Junko and Shirota, Hidekazu and Hayashi, Hideyuki and Kokuryo, Toshio and Yachida, Shinichi and Hirasawa, Akira and Kubo, Makoto and Kenmotsu, Hirotsugu and Tanabe, Masahiko and Ushiku, Tetsuo and Muto, Kaori and Seto, Yasuyuki and Oda, Katsutoshi},
title = {Patient survey on cancer genomic medicine in Japan under the national health insurance system},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {3},
pages = {954--962},
doi = {10.1111/cas.16065}
}
EUVIMED